Base de dados : MEDLINE
Pesquisa : E02.319.267.510.555 [Categoria DeCS]
Referências encontradas : 235 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 24 ir para página                         

  1 / 235 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390474
[Au] Autor:Liu B; Sun W; Wang K
[Ad] Endereço:Department of Parenteral and Enteral Nutrition, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
[Ti] Título:A successful insertion of PICC in patient with cardiac angiosarcoma and neoplasty of right atrium and pacemaker: A case report.
[So] Source:Medicine (Baltimore);96(51):e9225, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Primary cardiac angiosarcoma is a rare tumor and the common treatment is surgical resection followed by chemotherapy. Peripherally inserted central venous catheters (PICCs) are widely used in cancer patients and ultrasound-guided PICC insertion could improve success rate especially in patient with abnormal anatomy structure. Reports about PICCs being placed in patient who had suffered from the cardiac angiosarcoma and neoplasty of right atrium with an ipsilateral cardiac permanent pacemaker are rarely.After patient's informed consent, we present a case of the successful insertion of PICC into a patient with the ipsilateral cardiac disease with a pacemaker placement, which has not been previously reported. CONCLUSIONS: This report highlights PICC could be used in patient with cardiac disease with a pacemaker placement for chemotherapy.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Cateterismo Periférico/métodos
Cateteres Venosos Centrais
Neoplasias Cardíacas/terapia
Hemangiossarcoma/terapia
Marca-Passo Artificial
[Mh] Termos MeSH secundário: Terapia Combinada
Feminino
Seguimentos
Átrios do Coração/efeitos dos fármacos
Neoplasias Cardíacas/diagnóstico
Hemangiossarcoma/diagnóstico
Seres Humanos
Infusões Intralesionais
Meia-Idade
Doenças Raras
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009225


  2 / 235 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29215523
[Au] Autor:Sugarman J; Anderson J; Baschat AA; Herrera Beutler J; Bienstock JL; Bunchman TE; Desai NM; Gates E; Goldberg A; Grimm PC; Henry LM; Jelin EB; Johnson E; Hertenstein CB; Mastroianni AC; Mercurio MR; Neu A; Nogee LM; Polzin WJ; Ralston SJ; Ramus RM; Singleton MK; Somers MJG; Wang KC; Boss R
[Ad] Endereço:Berman Institute of Bioethics, the Department of Gynecology and Obstetrics, the Center for Fetal Therapy, the Department of Surgery, Pediatric Palliative Care, the Division of Pediatric Nephrology, the Division of Neonatology, and the Human Research Protection Program, Johns Hopkins School of Medicine and University, Baltimore, Maryland; U.S. House of Representatives, Southwest Washington 3rd District, Washington, DC; the Department of Pediatric Nephrology, Transplantation and Rheumatology, Children's Hospital of Richmond, the Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, Virginia; the Department of Obstetrics, Gynecology and Reproductive Services, University of California, San Francisco, San Francisco, California; the Department of Pediatrics-Nephrology, Max Rady College of Medicine, Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada; Francis King Carey School of Law, University of Maryland, Baltimore, Maryland; the Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California; the University of Washington School of Law and Institute for Public Health Genetics, Seattle, Washington; the Division of Neonatal-Perinatal Medicine and Program for Biomedical Ethics, Yale University School of Medicine, New Haven, Connecticut; Cincinnati Fetal Center, TriHealth Good Samaritan Hospital, Cincinnati, Ohio; the Department of Obstetrics and Gynecology, Pennsylvania Hospital, Philadelphia, Pennsylvania; and the Division of Nephrology, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts.
[Ti] Título:Ethical Considerations Concerning Amnioinfusions for Treating Fetal Bilateral Renal Agenesis.
[So] Source:Obstet Gynecol;131(1):130-134, 2018 Jan.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Congenital bilateral renal agenesis has been considered a uniformly fatal condition. However, the report of using serial amnioinfusions followed by the live birth in 2012 and ongoing survival of a child with bilateral renal agenesis has generated hope, but also considerable controversy over an array of complex clinical and ethical concerns. To assess the ethical concerns associated with using serial amnioinfusions for bilateral renal agenesis, we assembled a multidisciplinary group to map the ethical issues relevant to this novel intervention. The key ethical issues identified were related to 1) potential risks and benefits, 2) clinical care compared with innovation compared with research, 3) counseling of expectant parents, 4) consent, 5) outcome measures, 6) access and justice, 7) conflicts of interest, 8) effects on clinicians, 9) effects on institutions, and 10) long-term societal implications. These ethical issues should be addressed in conjunction with systematic efforts to examine whether this intervention is safe and effective. Future work should capture the experiences of expectant parents, women who undergo serial amnioinfusions, those born with bilateral renal agenesis and their families as well as clinicians confronted with making difficult choices related to it.
[Mh] Termos MeSH primário: Âmnio
Anormalidades Congênitas/diagnóstico por imagem
Anormalidades Congênitas/terapia
Infusões Intralesionais/ética
Nefropatias/congênito
Rim/anormalidades
Oligo-Hidrâmnio/terapia
Resultado da Gravidez
[Mh] Termos MeSH secundário: Feminino
Doenças Fetais/diagnóstico por imagem
Doenças Fetais/terapia
Seres Humanos
Consentimento Livre e Esclarecido
Rim/diagnóstico por imagem
Nefropatias/diagnóstico por imagem
Nefropatias/terapia
Saúde Materna
Oligo-Hidrâmnio/diagnóstico por imagem
Gravidez
Medição de Risco
Ultrassonografia Pré-Natal/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002416


  3 / 235 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28598907
[Au] Autor:Sinha S; Schreiner AJ; Biernaskie J; Nickerson D; Gabriel VA
[Ad] Endereço:From the Division of Physical Medicine and Rehabilitation, Departments of Clinical Neurosciences, Pediatrics and Surgery, Faculty of Medicine (S.S., V.A.G.) Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine (S.S., J.B.), Faculty of Medicine (A.J.S., V.A.G.), University of Calgary, Alberta, Canada; Calgary Firefighters' Burn Treatment Centre (D.N., V.A.G.); and Section of Plastic Surgery, Department of Surgery (D.N.), University of Calgary, Alberta, Canada.
[Ti] Título:Treating pain on skin graft donor sites: Review and clinical recommendations.
[So] Source:J Trauma Acute Care Surg;83(5):954-964, 2017 Nov.
[Is] ISSN:2163-0763
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Split-thickness skin grafting is the most common reconstructive procedure in managing burn injuries. Harvesting split-thickness skin creates a new partial thickness wound referred to as the donor site. Pain at the donor site is reported to be one of the most distressing symptoms during the early postoperative period. Here, we (a) identify strategies for managing donor site pain, (b) assess the quality of individual studies, and (c) formulate evidence-based recommendations based on the amount and consistency of evidence. Our analysis revealed five distinct approaches to minimize donor site pain. These include: continuous subcutaneous local anesthetic infusion (three studies), subcutaneous anesthetic injection (five studies), topical agents (six studies), nonpharmacological interventions (three studies), and wound dressings (18 studies). Available randomized control trials typically evaluated pain on standardized scales (i.e. Visual Analog Scale, Numerical Rating Scale), and compared the experimental group with standard care. Recommended treatments include: (a) subcutaneous anesthetic injection of adrenaline-lidocaine; (b) ice application; (c) topical agents, such as lidocaine and bupivacaine; and (d) hydrocolloid- and polyurethane-based wound dressings accompanied with fibrin sealant. Methodologically sound randomized control trials examining the efficacy of modified tumescent solution, ropivacaine, plasma therapy, noncontact ultrasound, and morphine gels are lacking and should be a priority for future research.
[Mh] Termos MeSH primário: Anestésicos Locais/uso terapêutico
Bandagens
Crioterapia
Manejo da Dor
Transplante de Pele/efeitos adversos
[Mh] Termos MeSH secundário: Autoenxertos
Queimaduras/cirurgia
Seres Humanos
Infusões Intralesionais
Injeções Intralesionais
Dor/etiologia
Complicações Pós-Operatórias/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anesthetics, Local)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170610
[St] Status:MEDLINE
[do] DOI:10.1097/TA.0000000000001615


  4 / 235 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28550928
[Au] Autor:Dhanapal B; Sistla SC; Badhe AS; Ali SM; Ravichandran NT; Galidevara I
[Ad] Endereço:Department of General Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
[Ti] Título:Effectiveness of continuous wound infusion of local anesthetics after abdominal surgeries.
[So] Source:J Surg Res;212:94-100, 2017 May 15.
[Is] ISSN:1095-8673
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To assess the effectiveness of continuous preperitoneal wound infusion of local anesthetic drug bupivacaine in providing pain relief, reducing opioid consumption, and enhancing postoperative recovery. METHODS: Eligible patients were randomly allocated to two groups (study group: bupivacaine and control group: normal saline). There were 47 patients in each group. The patients received continuous infusion of either 0.25% bupivacaine or 0.9% normal saline at 6 mL/h, for 48 h, based on their group allocation, through a multiholed wound infiltration catheter placed preperitoneally. All patients also received intravenous morphine through patient-controlled analgesia pump. Pain scores at rest and on cough, morphine consumption, and peak expiratory flow rate were assessed at 12, 24, and 48 h postoperatively. The time to first perception of bowel sounds and first passage of flatus was noted. All patients were assessed for postoperative nausea and vomiting and any local or systemic complications. Chi-square test was used to compare categorical variables. The morphine consumption was compared using Student t-test, the visual analogue scale (VAS) scores were compared using repeated-measures analysis of variance. RESULTS: The mean total morphine consumption in the study group was significantly lower than the control group (18.8 ± 2.21 versus 30.8 ± 2.58 mg, P = 0.001). The median VAS scores were significantly lower in the study group than those in the control group both at rest (3 [1-4] versus 4 [2-5], P = 0.04) and during cough (4 [3-6] versus 6 [4-6] P = 0.03), except at 48 h, when the median VAS score at rest was similar (3 [1-4] versus 3 [2-4], P = 0.56). Bowel function returned earlier in study group (67.34 ± 2.61 versus 76.34 ± 5.29 h, P = 0.03). Postoperative nausea and vomiting was less in study group. Respiratory function, assessed by peak expiratory flow rate, was better in the study group (192.55 ± 12.93 versus 165.31 ± 9.32 mL, P = 0.03). The incidence of surgical site infection was similar in both the groups (3/47 versus 5/47, P = 0.06). There was no systemic toxicity of local anesthetic. CONCLUSION: Continuous preperitoneal wound infusion of local anesthetic provides effective analgesia, reduces morphine consumption and its associated side effects, and enhances the postoperative recovery by reducing the incidence of prolonged postoperative ileus.
[Mh] Termos MeSH primário: Abdome/cirurgia
Anestésicos Locais/administração & dosagem
Bupivacaína/administração & dosagem
Dor Pós-Operatória/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Analgésicos Opioides/uso terapêutico
Anestésicos Locais/uso terapêutico
Bupivacaína/uso terapêutico
Método Duplo-Cego
Esquema de Medicação
Quimioterapia Combinada
Feminino
Seguimentos
Seres Humanos
Infusões Intralesionais
Infusões Parenterais
Masculino
Meia-Idade
Morfina/uso terapêutico
Medição da Dor
Estudos Prospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Anesthetics, Local); 76I7G6D29C (Morphine); Y8335394RO (Bupivacaine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170529
[St] Status:MEDLINE


  5 / 235 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28213004
[Au] Autor:Sakaguchi H; Ishida H; Nitanda H; Yamazaki N; Kaneko K; Kobayashi K
[Ad] Endereço:Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
[Ti] Título:Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
[So] Source:Lung Cancer;104:70-74, 2017 Feb.
[Is] ISSN:1872-8332
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Malignant pleural effusion (MPE) has a poor prognosis. Most patients are treated with tube thoracostomy and sclerotherapy, although its success rate is around 64%. We have investigated intrapleural perfusion with hyperthermic chemotherapy (IPHC) using cisplatin in a study with a pharmacokinetic evaluation. METHODS: Patients with MPE, performance status of 0-1, possibility of good lung expansion and Cr<1.2mg/dL were treated with IPHC. The circuit was filled with 2000mL of normal saline containing cisplatin at a dose of 80mg/m . Under video-assisted thoracoscopic surgery, the thoracic cavity was filled and perfused at a speed of approximately 1L/min at a temperature of 43°C for 1h. Perfusion solution and plasma samples were periodically collected, and concentrations of protein-unbound (free) platinum, which was the active derivative of cisplatin, and total platinum were determined by flameless atomic absorption spectrometry. RESULTS: Twenty patients with MPE (8 lung cancers, 7 mesotheliomas, and 5 others) were enrolled in this study. Rate of free platinum concentration relative to total platinum concentration in perfusion solution after 1hr IPHC at 43°C was 61.1±12.9%. Area under curve (AUC) of free platinum in the pleural space was calculated to be 26.3µg/mLxh, resulting in complete control of pleural effusion for 3 months after IHPC in all cases (95% confidence interval: 83-100%). While, absorption rate of total platinum from the pleural space was 33.8±17.0% (27.4±13.6mg/m ), and the maximum concentration of total platinum in serum was low, 0.66±0.31µg/mL, resulting in controllable side effects; grade 1 renal toxicity: 6 patients, grade 1 emesis: 7 patients. CONCLUSIONS: IPHC with cisplatin showed favorable pharmacokinetic profiles for an optional treatment to control malignant pleural effusion.
[Mh] Termos MeSH primário: Cisplatino/farmacocinética
Hipertermia Induzida/métodos
Neoplasias Pulmonares/tratamento farmacológico
Perfusão/métodos
Cavidade Pleural/efeitos dos fármacos
Derrame Pleural Maligno/tratamento farmacológico
Cirurgia Torácica Vídeoassistida/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Cisplatino/administração & dosagem
Cisplatino/efeitos adversos
Cisplatino/farmacologia
Feminino
Seres Humanos
Hipertermia Induzida/efeitos adversos
Infusões Intralesionais/efeitos adversos
Infusões Intralesionais/instrumentação
Neoplasias Pulmonares/complicações
Neoplasias Pulmonares/patologia
Neoplasias Pulmonares/cirurgia
Masculino
Mesotelioma/tratamento farmacológico
Meia-Idade
Perfusão/efeitos adversos
Platina/uso terapêutico
Derrame Pleural Maligno/patologia
Neoplasias Pleurais/tratamento farmacológico
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
49DFR088MY (Platinum); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170219
[St] Status:MEDLINE


  6 / 235 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28045657
[Au] Autor:Pi Sala N; Figueras Suriol A; Ramió Montero E
[Ad] Endereço:Farmacéutica adjunta, Servicio de Farmacia, Hospital Universitari Sagrat Cor, Barcelona.. npisala@gmail.com.
[Ti] Título:[Intralesional cidofovir in human papilomavirus infection in interdigital spaces].
[Ti] Título:Cidofovir intralesional en infección por el virus del papiloma humano en espacios interdigitales..
[So] Source:Farm Hosp;41(n01):132-133, 2017 Jan 01.
[Is] ISSN:0214-753X
[Cp] País de publicação:Spain
[La] Idioma:spa
[Mh] Termos MeSH primário: Antivirais/administração & dosagem
Antivirais/uso terapêutico
Citosina/análogos & derivados
Organofosfonatos/administração & dosagem
Organofosfonatos/uso terapêutico
Infecções por Papillomavirus/tratamento farmacológico
Dermatopatias Virais/tratamento farmacológico
Verrugas/tratamento farmacológico
[Mh] Termos MeSH secundário: Citosina/administração & dosagem
Citosina/uso terapêutico
Dedos
Seres Humanos
Infusões Intralesionais
Masculino
Meia-Idade
Infecções por Papillomavirus/virologia
Dermatopatias Virais/virologia
Verrugas/virologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); 0 (Organophosphonates); 8J337D1HZY (Cytosine); JIL713Q00N (cidofovir)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170104
[St] Status:MEDLINE
[do] DOI:10.7399/fh.2017.41.1.10645


  7 / 235 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27046461
[Au] Autor:Ekmekçi P; Çaglar GS; Yilmaz H; Kazbek BK; Gursoy AY; Kiseli M; Tüzüner F
[Ad] Endereço:a Department of Anesthesiology and Reanimation and.
[Ti] Título:Effects of different doses of tramadol added to levobupivacaine in continuous wound infusion for postoperative pain treatment following cesarean section.
[So] Source:J Matern Fetal Neonatal Med;30(3):343-346, 2017 Feb.
[Is] ISSN:1476-4954
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to compare the effects of two different doses of tramadol added to levobupivacaine as continuous wound infusion, on VAS scores following cesarean section. METHODS: The study was conducted in an University Hospital and was approved by the Local Ethical Committee. Sixty-five ASA I-II parturients, between 18 and 45 years were enrolled. The participants were randomized to three groups. Group T1 (n = 21) was given the study solution consisting of levobupivacaine 0.25% + tramadol 1 mg/kg. Group T2 (n = 21) was given levobupivacaine 0.25% + tramadol 2 mg/kg and Group L (n = 21) was given levobupivacaine 0.25%, subcutaneously, alone. Each patient who delivered by cesarean section was applied a triple orifice epidural catheter above rectus fascia for continious wound infiltration. VAS at rest and with 20 degrees leg lift, time to first additional analgesic, total additional analgesic consumption, side effects, and sedation scores were recorded. RESULTS: There were no statistically significant differences among groups, concerning VAS scores at rest and VAS scores at leg lift. Total amount of additional analgesics and sedation scores were also similar for three groups. CONCLUSION: Different doses of tramadol as adjunct to local anesthetics in continuous wound infiltration following cesarean section do not seem to provide superior analgesia.
[Mh] Termos MeSH primário: Analgésicos Opioides/administração & dosagem
Anestésicos Locais/administração & dosagem
Bupivacaína/análogos & derivados
Cesárea
Dor Pós-Operatória/tratamento farmacológico
Tramadol/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Analgésicos Opioides/uso terapêutico
Anestésicos Locais/uso terapêutico
Bupivacaína/administração & dosagem
Bupivacaína/uso terapêutico
Relação Dose-Resposta a Droga
Método Duplo-Cego
Quimioterapia Combinada
Feminino
Seres Humanos
Infusões Intralesionais
Meia-Idade
Medição da Dor
Dor Pós-Operatória/diagnóstico
Satisfação do Paciente/estatística & dados numéricos
Gravidez
Tramadol/uso terapêutico
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Anesthetics, Local); 39J1LGJ30J (Tramadol); A5H73K9U3W (levobupivacaine); Y8335394RO (Bupivacaine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170524
[Lr] Data última revisão:
170524
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160406
[St] Status:MEDLINE


  8 / 235 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27085278
[Au] Autor:Kokavec J; Rajak S; Huilgol S; Selva D
[Ad] Endereço:South Australian Institute of Ophthalmology, North Terrace, Adelaide, Australia. Electronic address: jkokavec@gmail.com.
[Ti] Título:Pyoderma gangrenosum of the eyelid.
[So] Source:Can J Ophthalmol;51(2):e58-60, 2016 Apr.
[Is] ISSN:1715-3360
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças Palpebrais/complicações
Pioderma Gangrenoso/complicações
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Fármacos Dermatológicos/administração & dosagem
Quimioterapia Combinada
Doenças Palpebrais/diagnóstico
Doenças Palpebrais/tratamento farmacológico
Feminino
Glucocorticoides/administração & dosagem
Seres Humanos
Infliximab/administração & dosagem
Infusões Intralesionais
Prednisolona/administração & dosagem
Pioderma Gangrenoso/diagnóstico
Pioderma Gangrenoso/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Glucocorticoids); 9PHQ9Y1OLM (Prednisolone); B72HH48FLU (Infliximab)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160418
[St] Status:MEDLINE


  9 / 235 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo SciELO Brasil
[PMID]:26910353
[Au] Autor:Queiroz DP; Carollo CA; Kadri MC; Rizk YS; Araujo VC; Monteiro PE; Rodrigues PO; Oshiro ET; Matos Mde F; Arruda CC
[Ad] Endereço:Laboratório de Parasitologia Humana, Centro de Ciências Biológicas e da Saúde, Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil.
[Ti] Título:In vivo antileishmanial activity and chemical profile of polar extract from Selaginella sellowii.
[So] Source:Mem Inst Oswaldo Cruz;111(3):147-54, 2016 Mar.
[Is] ISSN:1678-8060
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:The polar hydroethanolic extract from Selaginella sellowii(SSPHE) has been previously proven active on intracellular amastigotes (in vitro test) and now was tested on hamsters infected with Leishmania (Leishmania) amazonensis (in vivo test). SSPHE suppressed a 100% of the parasite load in the infection site and draining lymph nodes at an intralesional dose of 50 mg/kg/day × 5, which was similar to the results observed in hamsters treated with N-methylglucamine antimonate (Sb) (28 mg/Kg/day × 5). When orally administered, SSPHE (50 mg/kg/day × 20) suppressed 99.2% of the parasite load in infected footpads, while Sb suppressed 98.5%. SSPHE also enhanced the release of nitric oxide through the intralesional route in comparison to Sb. The chemical fingerprint of SSPHE by high-performance liquid chromatography with diode-array detection and tandem mass spectrometry showed the presence of biflavonoids and high molecular weight phenylpropanoid glycosides. These compounds may have a synergistic action in vivo. Histopathological study revealed that the intralesional treatment with SSPHE induced an intense inflammatory infiltrate, composed mainly of mononuclear cells. The present findings reinforce the potential of this natural product as a source of future drug candidates for American cutaneous leishmaniasis.
[Mh] Termos MeSH primário: Antiprotozoários/farmacologia
Leishmania/efeitos dos fármacos
Extratos Vegetais/química
Selaginellaceae/química
[Mh] Termos MeSH secundário: Administração Oral
Animais
Antiprotozoários/isolamento & purificação
Biflavonoides/análise
Cromatografia Líquida de Alta Pressão
Cricetinae
Drenagem
/parasitologia
Glicosídeos/química
Infusões Intralesionais
Leucócitos Mononucleares/parasitologia
Macrófagos/parasitologia
Masculino
Meglumina/administração & dosagem
Óxido Nítrico/análise
Compostos Organometálicos/administração & dosagem
Carga Parasitária
Extratos Vegetais/administração & dosagem
Solventes
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antiprotozoal Agents); 0 (Biflavonoids); 0 (Glycosides); 0 (Organometallic Compounds); 0 (Plant Extracts); 0 (Solvents); 31C4KY9ESH (Nitric Oxide); 6HG8UB2MUY (Meglumine); 75G4TW236W (meglumine antimoniate)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160225
[St] Status:MEDLINE


  10 / 235 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26898499
[Au] Autor:Tykocki T; Miekisiak G
[Ad] Endereço:Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland. Electronic address: ttomasz@mp.pl.
[Ti] Título:Application of Convection-Enhanced Drug Delivery in the Treatment of Malignant Gliomas.
[So] Source:World Neurosurg;90:172-178, 2016 Jun.
[Is] ISSN:1878-8769
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Convection-enhanced delivery (CED) is a promising new method of local drug delivery therapy for a diverse type of antitumor agents. CED offers significant advantages over systemic chemotherapy by bypassing the blood-brain barrier and obtaining adequate drug concentration with limited systemic toxicity. Actually, there is no effective treatment of malignant gliomas (MGs); survival rates remain poor despite decades of clinical trials. Conventional chemotherapy has been found to be minimally effective in the control of MG progression. CED involves the implantation of catheters through which conventional and novel therapeutic formulations can be delivered directly to the tumor using continuous, low-positive-pressure bulk flow. On the basis of the preclinical and clinical studies, we demonstrated that CED could produce effective drug delivery to large brain and tumor areas. However, clinical studies to date have not found any substantial improvement in overall survival in the treatment of MG. This overview presents up-to-date clinical results in the treatment of MG by the application of CED.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/tratamento farmacológico
Cateterismo Periférico/métodos
Preparações de Ação Retardada/administração & dosagem
Glioma/tratamento farmacológico
Infusões Intralesionais/métodos
[Mh] Termos MeSH secundário: Neoplasias Encefálicas/patologia
Cateterismo Periférico/instrumentação
Desenho de Equipamento
Medicina Baseada em Evidências
Feminino
Glioma/patologia
Seres Humanos
Infusões Intralesionais/instrumentação
Masculino
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Delayed-Action Preparations)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170830
[Lr] Data última revisão:
170830
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160223
[St] Status:MEDLINE



página 1 de 24 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde